Clinical trial
A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression
NCT00852202 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2009
- Completion date
- June 15, 2010
- Enrollment
- 234 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.
bipolar depression